[Click eStock] "HEM Pharma, a Domestic Microbiome Stock Highlighted by Bill Gates"

On August 27, independent research firm ValueFinder analyzed that HEM Pharma is a domestic stock related to the microbiome industry, which Bill Gates has highlighted, and emphasized the need to pay attention to the company's increasingly visible leap into the global market.

HEM Pharma was founded in 2016 and was listed on the KOSDAQ market last year. It is a microbiome healthcare and new drug development company based on the PMAS platform. In 2020, it succeeded in signing a 20-year exclusive contract with Amway, a global network marketing company, for customized healthcare products, and has continued to commercialize its technology.

In addition, the company has formed strategic partnerships with major domestic and international corporations such as Celltrion, Cosmax, and Chong Kun Dang Bio. It is also preparing to export its MyLab service to the United States, Japan, and Southeast Asia next year, raising expectations for global expansion.

It has been revealed that approximately 39 trillion microorganisms exist in the human gut, and since each person has a unique microbiome, the need for personalized healthcare in the medical industry is being highlighted. In 2018, Bill Gates, founder of Microsoft, cited three keywords that would change the world at the JP Morgan Healthcare Conference: microbiome, dementia treatments, and immuno-oncology drugs.

Lee Chungheon, a researcher at ValueFinder, stated, "HEM Pharma has two pipelines: HEMP-001, a depression treatment, and HEMP-002, a treatment for low anterior resection syndrome (LARS)." He explained, "These pipelines have received IND approval for phase 2a clinical trials, and the company is currently in discussions with multiple global partners regarding technology transfer and joint development."

He added, "In July, the company invested approximately 7 billion won to complete a new factory in Sejong, enabling the internal production of microbiome-based health functional foods and preparing to meet global demand, thereby accelerating its global business."